Supply Chain Intelligence

VYNE Therapeutics Inc. Supply Chain

VYNE supply chain intelligence for VYNE Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

VYNE ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
3Customers
2Debt Items
12Related Chains

VYNE Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
TAY TAY 90% The Company will pay tiered royalties to Tay on net sales of such licensed products by the Company, its affiliates, or sublicensees
CUTIA-THERAPEUTICS-HK-LIMITED CUTIA-THERAPEUTICS-HK-LIMITED 80% the license agreement with Cutia Therapeutics (HK) Limited
DERM Journey Medical Corporation 72% Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operations. Our human capital management objectives include, as applicable, identifying, r…
EDSA Edesa Biotech, Inc. 72% Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…

VYNE Therapeutics Inc. Customers

TickerNameConfidenceEvidence
JOURNEY JOURNEY 90% the Company sold its MST Franchise to Journey
DERM Journey Medical Corporation 72% Reciprocal relationship from DERM graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operatio…
EDSA Edesa Biotech, Inc. 72% Reciprocal relationship from EDSA graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from EDSA graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from EDSA g…

VYNE Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
VYNE-DEBT-13485 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
VYNE-DEBT-13484 Warrants outstanding: 27509 90% xbrl warrant detail from xbrl 2026-03-31.

VYNE Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for VYNE Therapeutics Inc..

VYNE Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
VYNE-OWNER-ANSON-FUNDS-MANAGEMENT-LP Anson Funds Management LP 90% 13F overlay lists Anson Funds Management LP as top holder; 46 tracked holders.

VYNE Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
MESO Mesoblast Limited 100.00 2
MRK Merck & Co., Inc. 100.00 2
CMMB Chemomab Therapeutics Ltd. 100.00 2
DERM Journey Medical Corporation 100.00 1 ['customer', 'supplier']
ACRS Aclaris Therapeutics, Inc. 100.00 2
LLY Eli Lilly and Company 100.00 2
CMOS CMOS 50.00 2
ORANY ORANGE 50.00 2
FBIO Fortress Biotech, Inc. 50.00 2
EDSA Edesa Biotech, Inc. 36.29 1 ['customer', 'supplier']
CM Canadian Imperial Bank of Commerce 14.78 2
View VYNE supply chain intel →

Explore the full interactive supply chain map for VYNE Therapeutics Inc..

Open VYNE supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map